30-MAY-2023 6:10

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S1801-Melan, Adv, Adj vs Neoadj Pembrolizumab 1 N 1 Adjuvant Arm 342 173 0 0 0 0 0 02/15/2019 271 104
        2 Neoadjuvant Pembrolizumab   172 0 0 0 0 0      
            345 0 0 0 0 0      
 
    2 Y 3 Surgery   316 9 0 0 0 0 02/15/2019    
            316 9 0 0 0 0      
 
    3 Y 4 Post-Surgery Pembro   267 17 0 0 0 0 02/15/2019    
            267 17 0 0 0 0      
 
  S2000-MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo 1 Y 1 Encorafenib/Binimetinib/Nivolu 35 13 8 2 1 0 0 01/06/2021 122 47
        2 Ipilimumab + Nivolumab   15 9 3 1 0 0      
            28 17 5 2 0 0      
 
Yes EA6141-Melan, Adv, Nivolumab+Ipi ± Sargmostim 1 E Total Registrations   51 5 2 2 2 0 03/25/2016 218 87
            51 5 2 2 2 0      
 
No S2015-MELAN, Stg I-II, 1cm v 2cm excision margins 1 E Total Registrations   195 191 145 72 29 7 05/12/2022 170 64
            195 191 145 72 29 7      
 
  A091903-Melan, Resected Mucosal, Adj Nivo +/- Cabo 0 E Total Registrations   1 1 0 0 0 0 11/01/2022 68 33
            1 1 0 0 0 0      
 
    1 E Total Registrations   1 1 0 0 0 0 11/01/2022    
            1 1 0 0 0 0      
 
  EA6174-Merkel, Adjuvant Pembrolizumab vs Observation 1 E Total Registrations   53 11 3 2 0 0 05/01/2019 299 108
            53 11 3 2 0 0      
 
  EA6192-Melan, Adv, Erly Discont of Antibdy Thrpy 0 E Total Registrations   7 5 2 0 0 0 09/22/2021 124 49
            7 5 2 0 0 0      
 
    1 E Total Registrations   8 5 2 0 0 0 09/22/2021    
            8 5 2 0 0 0